Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLN NASDAQ:ATXI NASDAQ:KRBP NASDAQ:PBLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AATXIAvenue Therapeutics$0.42+17.1%$0.26$0.17▼$3.93$1.34M-0.08129,983 shs8,345 shsKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsPBLAPanbela Therapeutics$0.16-13.9%$0.24$0.10▼$0.47$777K1.3418,160 shs2,970 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-14.27%ATXIAvenue Therapeutics+17.06%+15.07%+61.85%+58.43%-88.11%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-89.34%PBLAPanbela Therapeutics-13.93%-23.85%-31.03%-42.86%-54.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics2.0686 of 5 stars0.04.00.04.61.00.01.9KRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.2854 of 5 stars0.05.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/AATXIAvenue Therapeutics 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/APBLAPanbela Therapeutics 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09ATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AKRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/AATXIAvenue Therapeutics-$10.38M-$7.490.02∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)KRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05ATXIAvenue TherapeuticsN/A2.702.70KRBPKiromic BioPharmaN/A0.160.22PBLAPanbela TherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%ATXIAvenue Therapeutics17.34%KRBPKiromic BioPharma10.91%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%ATXIAvenue Therapeutics1.80%KRBPKiromic BioPharma20.59%PBLAPanbela Therapeutics0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableKRBP, ASLN, PBLA, and ATXI HeadlinesRecent News About These CompaniesPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.dePanbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comPanbela Therapeutics (OTC:PBLA) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comHorace Mann Educators (NYSE:HMN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPanbela Therapeutics (OTC:PBLA) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | insidermonkey.comPanbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q2 2024 Financial ResultsAugust 13, 2024 | globenewswire.comIs Panbela Therapeutics Inc (PBLA) Stock a Good Investment?August 3, 2024 | aaii.comAPanbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024July 30, 2024 | globenewswire.comPanbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationJune 24, 2024 | globenewswire.comPanbela Therapeutics Inc. (PBLA) Insider ActivityMay 25, 2024 | nasdaq.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 17, 2024 | msn.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | uk.finance.yahoo.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 16, 2024 | finance.yahoo.comPanbela Provides Business Update and Reports Q1 2024 Financial ResultsMay 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeKRBP, ASLN, PBLA, and ATXI Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 07/16/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Avenue Therapeutics NASDAQ:ATXI$0.42 +0.06 (+17.06%) As of 07/18/2025 03:57 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Panbela Therapeutics NASDAQ:PBLA$0.16 -0.03 (-13.93%) As of 07/18/2025 03:46 PM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
